T-cell receptor gene therapy for cancer

T细胞受体基因治疗癌症

• 批准号: 10014697
• 负责人: Christian Hinrichs
• 金额: $ 285.85万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10014697
• 关键词: Clinic; Genetic; Genetic Engineering; Goals; Knowledge; Malignant Neoplasms; Patients; Research; Resistance; T-Cell Receptor Genes; T-Lymphocyte; Technology; Testing; Translational Research; Treatment Efficacy; Tumor Antigens; Work; bench to bedside; cancer therapy; effective therapy; engineered T cells; innovation; next generation; response; response biomarker

We have identified the genetic sequences of TCRs that target tumor antigens. We are testing genetically engineered T cells that express these TCRs for the treatment of patients with cancer. Our research is focused and on understanding response and resistance to these treatments with the goal to use this knowledge to develop more effective treatments. This work includes the discovery of technologies to identify biomarkers of response, enhance the efficacy of therapeutic T cells, and target new tumor antigens.

我们已经确定了靶向肿瘤抗原的TCR的基因序列。我们正在测试表达这些TCR的基因工程T细胞，用于治疗癌症患者。我们的研究重点是了解对这些治疗的反应和抵抗力，目的是利用这些知识开发更有效的治疗方法。这项工作包括发现识别反应生物标志物的技术，增强治疗性T细胞的功效，并靶向新的肿瘤抗原。